NovoTTF-100L(P) for Adenocarcinoma

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Adenocarcinoma+1 More
NovoTTF-100L(P) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment that uses electric fields to kill tumor cells. The treatment is given with gemcitabine and nab-paclitaxel, and is being tested to see if it is safe and effective.

Eligible Conditions
  • Adenocarcinoma

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Adenocarcinoma

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: 4 years

4 years
Local progression-free survival
Objective response rate
One-year survival rate
Overall survival
Pain-free survival
Progression-free survival
Puncture-free survival
Quality of life
Resectability rate
Toxicity profile

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Adenocarcinoma

Trial Design

2 Treatment Groups

Best Standard of Care
1 of 2
NovoTTF-100L(P)
1 of 2
Active Control
Experimental Treatment

556 Total Participants · 2 Treatment Groups

Primary Treatment: NovoTTF-100L(P) · No Placebo Group · Phase 3

NovoTTF-100L(P)Experimental Group · 3 Interventions: NovoTTF-100L(P), Gemcitabine, nab paclitaxel · Intervention Types: Device, Drug, Drug
Best Standard of CareActiveComparator Group · 2 Interventions: Gemcitabine, nab paclitaxel · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gemcitabine
FDA approved
Paclitaxel
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years

Who is running the clinical trial?

NovoCure Ltd.Lead Sponsor
52 Previous Clinical Trials
3,990 Total Patients Enrolled
3 Trials studying Adenocarcinoma
116 Patients Enrolled for Adenocarcinoma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have contact with the most proximal draining jejunal branch into the superior mesenteric vein.
You have a solid tumor that is in contact with the CA>180°.
The SMV/PV is not reconstructible due to tumor involvement or occlusion.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
References